201
|
Lueck HJ, Luebbe K, Bischoff J, Maass N, Feisel G, Tome O, Janni W, Aydogdu M, Neuhoeffer T, Ober A, Aktas B, Park-Simon TW, Schumacher C, Hoeffkes HG, Illmer T, Wagner H, Mehta K, Nekljudova V, Loibl S, Von Minckwitz G. A randomized phase III study to determine the efficacy of capecitabine in addition to a taxane and bevacizumab as first-line therapy in patients with metastatic breast cancer. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.1082] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1082 Background: Conventional chemotherapy combined with novel molecular targeted agents has been proven effective and tolerable in metastatic breast cancer (MBC). Taxanes (T) plus bevacizumab (B) and T plus capecitabine (X) showed a benefit in progression free survival (PFS) compared to T alone. Life-threatening or highly symptomatic situations require poly-chemotherapies in MBC patients; therefore a combination of all 3 drugs appears reasonable. Methods: TABEA (NCT01200212) is a prospective, randomized, open label, phase III trial comparing T plus B +/- X as 1st-line therapy in MBC. Patients with histologically confirmed HER2- locally advanced or MBC were included. All patients received T (paclitaxel 80 mg/m2 i.v. d1,8,15 q22 or docetaxel 75 mg/m2 i.v. d1 q22) and B (15 mg/kg i.v. d1 q22) (TB) and were randomized to X (1800 mg/m² daily d1-14 q22) in addition and concurrently to TB (TBX) or TB alone. Randomization was stratified by receptor status, planned taxane, and disease free interval (≤ or >12 months). Primary objective was PFS. Secondary objectives were response rate and duration, clinical benefit rate (CR, PR, stable disease ≥ 24 weeks), 3yr overall survival, PFS in patients ≥ 65 years, toxicity, and compliance. Sample size calculation assumed a PFS of 10 and 13.3 months for TB and TBX, respectively (HR=0.75) requiring 432 patients and 386 events with 2-sided α=0.05 and β=0.2. Interim analysis was planned after 25% of required events (n=96). Results: Planned interim futility and safety analyses after 100 documented events in 202 patients have shown no efficacy benefit and higher toxicity in the TBX arm. For PFS, HR=1.061, 95% CI (0.715, 1.576) was observed, futility boundary was crossed. Overall grade 3-4 adverse events (e.g., thrombopenia, diarrhea, hand-foot-syndrome) (72.3 vs. 57.4%, p=0.039)and serious adverse events (40.6 vs. 24.8%, p=0.016) rates were higher for TBX after 16.3 months median follow up. There were 6 deaths in the TBX vs. 1 in the TB arm. Recruitment and therapy were stopped on 5th Oct 2012 following the advice from the IDMC. Conclusions: TABEA failed to show an improvement using the 3 drug regimen TBX in high-risk MBC patients. Clinical trial information: NCT 01200212.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - Thomas Illmer
- Gemeinschaftspraxis Innere Medizin/Haematologie, Dresden, Germany
| | | | | | | | | | | | | |
Collapse
|
202
|
Barinoff J, Traut A, Bauerschlag D, Bischoff J, Herr D, Lübbe K, Lück HJ, Maass N, Mundhenke C, Schmidt M, Schwedler K, Thill M, Steffen J, Loibl S, von Minckwitz G. Chemotherapy for 70-Year-Old Women with Breast Cancer in Germany: A Survey by the German Breast Group. Geburtshilfe Frauenheilkd 2013; 73:433-439. [PMID: 24771923 PMCID: PMC3864474 DOI: 10.1055/s-0032-1328612] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2012] [Revised: 04/16/2013] [Accepted: 04/16/2013] [Indexed: 10/26/2022] Open
Abstract
Aim: Around half of all women in Germany with breast cancer are older than 65 and approximately one third of them is older than 70 years of age. In theory, the preferred therapeutic management of women with breast cancer aged 65 and above corresponds to that formulated for younger patients and complies with the S3 Guidelines and the therapy recommendations formulated by AGO. To study the current therapies used to treat women with breast cancer aged 70 and above in Germany, a survey of the clinics of the German Breast Group (GBG) was done. Method: An online survey was carried out with requests sent to 599 physicians registered as principal investigators in the database of the GBG. The 12-item questionnaire was used to investigate the systematic therapeutic management of 70-year-old patients in different settings. The indication for chemotherapy was taken as a given. Results: In a neoadjuvant setting, 62 % of physicians opted for anthracycline and taxane-based therapy as did 56.6 % of physicians in an adjuvant setting. One third of physicians preferred a taxane-based therapy with the anti-angiogenesis inhibitor bevacizumab as first-line therapy for primary metastatic cancer and after anthracycline-based therapy. Capecitabine (around 30 %) and navelbine (around 20 %) were proposed as second-line neoadjuvant and adjuvant therapies after prior anthracycline- and taxane-based therapy. Conclusion: The chemotherapy regimen prescribed for women with breast cancer aged 70 and above in Germany appears to be relatively standardised and corresponds to the recommendations given in the S3 Guidelines and by the AGO Breast Committee.
Collapse
Affiliation(s)
- J. Barinoff
- Gynäkologie und Gynäkologische Onkologie, Kliniken Essen Mitte,
Essen
| | - A. Traut
- Gynäkologie und Gynäkologische Onkologie, Kliniken Essen Mitte,
Essen
| | - D. Bauerschlag
- Frauenklinik für Gynäkologie und Geburtshilfe, Universitätsklinikum
Aachen, Aachen
| | - J. Bischoff
- Universitätsfrauenklinik, Universitätsklinikum Magdeburg A. ö. R,
Magdeburg
| | - D. Herr
- Klinik für Gynäkologie und Gynäkologische Onkologie,
Dr-Horst-Schmidt-Kliniken, Wiesbaden
| | - K. Lübbe
- Klinik für Gynäkologie und Geburtshilfe, Diakoniekrankenhaus
Henriettenstiftung, Hannover
| | - H.-J. Lück
- Gynäkologisch-Onkologische Schwerpunktpraxis, Hannover
| | - N. Maass
- Frauenklinik für Gynäkologie und Geburtshilfe, Universitätsklinikum
Aachen, Aachen
| | - C. Mundhenke
- Frauenklinik, Universitätsklinikum Schleswig-Holstein,
Kiel
| | - M. Schmidt
- Klinik und Poliklinik für Geburtshilfe und Frauenkrankheiten,
Universitätsmedizin Mainz, Mainz
| | - K. Schwedler
- Neue Frauenklinik, Luzerner Kantonsspital, Luzern,
Switzerland
| | - M. Thill
- Klinik für Gynäkologie und Geburtshilfe, Agaplesion Markus Krankenhaus,
Frankfurt am Main
| | | | - S. Loibl
- German Breast Group, Neu Isenburg
| | | |
Collapse
|
203
|
Pecks U, Caspers R, Sosnowsky K, Maass N, Rath W, Huppertz B. PP033. Oxidized LDL particles in the placenta of intrauterine growth restriction (IUGR) subgroups. Pregnancy Hypertens 2013; 3:78-9. [DOI: 10.1016/j.preghy.2013.04.060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
204
|
Pecks U, Hirshman S, Mohaupt M, Schlembach D, Maass N, Rath W, Escher G. PP031. The fetal cholesterol acceptor potential in cord sera of intrauterine growth restricted (IUGR) neonates. Pregnancy Hypertens 2013; 3:78. [PMID: 26105888 DOI: 10.1016/j.preghy.2013.04.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
INTRODUCTION The fetal umbilical cord blood cholesterol concentration is lower in IUGR neonates as compared to gestational age matched controls (CTRL). One possible explanation is an alteration of cholesterol acceptor concentration or functionality and a disturbed interaction with reverse cholesterol transport (RCT) mechanisms at the placentofetal interface. OBJECTIVE To study receptor specific mechanisms of RCT in response to fetal sera of IUGR and CTRL neonates. METHODES Different cell lines were used to determine the fractional efflux of (3)H-cholesterol in response to whole fetal serum (IUGR n=25; CTRL n=25) in the absence or presence of ABCA1 overexpression. Efflux values were correlated to serum concentrations of possible cholesterol acceptors like HDL, apoA1, and apoE. RESULTS The main finding was a significant over all reduction of fractional cholesterol efflux in response to IUGR serum as compared to CTRL (p<0.001). The differences were abolished after overexpression of ABCA1. Cholesterol efflux over all was highly correlated to HDL and ApoE concentration (n˜=0.777 and n˜=0.60). CONCLUSION The reduced cholesterol efflux acceptor capacity appears to diminish cholesterol availability and transplacental cholesterol transport to IUGR fetuses. Moreover, disturbances of RCT are involved in the pathomechanisms of atherosclerosis. Our results represent a link between the known association of being born small for gestational age and risk of developing CVD later in life.
Collapse
|
205
|
Pecks U, Wölter M, Borchers C, Smith D, Maass N, Glocker M, Rath W. PP032. Apolipoprotein profiling in umbilical cord blood of intrauterine growth restricted (IUGR) neonates. Pregnancy Hypertens 2013; 3:78. [PMID: 26105887 DOI: 10.1016/j.preghy.2013.04.059] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
INTRODUCTION Fetal umbilical cord HDL concentration is lower in IUGR neonates as compared to gestational age matched controls (CTRL). The causes by now are unknown. A full apolipoprotein analysis of cord blood might help in understanding the changes in lipid metabolism seen in IUGR. OBJECTIVE To characterize cord blood apolipoprotein profile of IUGR neonates. METHODS Serum of venous umbilical cord blood (15 IUGR vs. 15 CTRL) was analyzed by Multiple Reaction Monitoring (MRM). 15 different known apolipoproteins were profiled. HDL and LDL were measured by colorimetric methods in fetal cord blood and their corresponding mothers. RESULTS Fetal HDL (p<0.0001), ApoC1 (p<0.0001), and ApoE (p=0.0001) levels were lower in IUGR as compared to CTRL. Fetal HDL levels were positive correlated to ApoE, ApoC1, and ApoA2 (r=0.79, r=0.74, r=0.56). Fetal LDL levels were positive correlated to ApoB, ApoE, ApoA2, and ApoC3 (r=0.74, r=0.67, r=0.57, r=0.55). Maternal LDL concentrations correlated positive to fetal ApoC1, ApoC2, and LCAT-concentration (r=0.54, r=0.52, r=0.52). DISCUSSION The results underlines the relevance of ApoE in fetal development. Moreover, we speculate that maternal lipid profile has an impact on fetal lipid metabolisms as evidenced by the association of maternal LDL levels and fetal ApoC1, ApoC2, and LCAT concentrations. This observation requires further confirmation and is worth to be analyzed since it provides a mechanistic link for therapeutic options.
Collapse
|
206
|
Onkes W, Fredrik R, Micci F, Schönbeck BJ, Martin-Subero JI, Ullmann R, Hilpert F, Bräutigam K, Janssen O, Maass N, Siebert R, Heim S, Arnold N, Weimer J. Breakpoint characterization of the der(19)t(11;19)(q13;p13) in the ovarian cancer cell line SKOV-3. Genes Chromosomes Cancer 2013; 52:512-22. [DOI: 10.1002/gcc.22048] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2012] [Revised: 01/03/2013] [Accepted: 01/04/2013] [Indexed: 12/11/2022] Open
|
207
|
|
208
|
Lüftner D, Lux MP, Maass N, Schütz F, Schwidde I, Fasching PA, Fehm T, Janni W, Kümmel S, Kolberg HC. Advances in Breast Cancer - Looking Back over the Year. Geburtshilfe Frauenheilkd 2012; 72:1117-1129. [PMID: 26640285 PMCID: PMC4651151 DOI: 10.1055/s-0032-1328084] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2012] [Revised: 12/03/2012] [Accepted: 12/03/2012] [Indexed: 12/12/2022] Open
Abstract
Treatment options as well as the characteristics for therapeutic decisions in patients with primary and advanced breast cancer are increasing in number and variety. New targeted therapies in combination with established chemotherapy schemes are broadening the spectrum, yet not every new, promising combination achieves a better result. New data from the field of pharmacogenomics point to prognostic and predictive factors that take not only the properties of the tumour but also the genetic disposition of the patient into consideration. Current therapeutic decision-making is thus based on a combination of classical clinical and modern molecular biomarkers. Health-economic concerns are also being taken into consideration more frequently, meaning political decisions may also become a factor. This review presents the trends over the past year.
Collapse
Affiliation(s)
- D. Lüftner
- Medizinische Klinik und Poliklinik II, Campus Charité Mitte, Berlin
| | - M. P. Lux
- Frauenklinik, Universitätsklinikum Erlangen, Erlangen
| | - N. Maass
- Department of Gynecology and Obstetrics, University Hospital Aachen
| | - F. Schütz
- Frauenklinik, Universitätsklinikum Heidelberg, Heidelberg
| | - I. Schwidde
- Klinik für Senologie/Brustzentrum, Klinikum Essen-Mitte, Essen
| | - P. A. Fasching
- Department of Gynecology and Obstetrics, University Hospital Erlangen, Erlangen
| | - T. Fehm
- Department of Obstetrics and Gynecology, University Tübingen, Tübingen
| | - W. Janni
- Frauenklinik, Klinikum der Universität Ulm, Ulm
| | - S. Kümmel
- Klinik für Senologie/Brustzentrum, Klinikum Essen-Mitte, Essen
| | - H.-C. Kolberg
- Klinik für Gynäkologie und Geburtshilfe, Marienhospital Bottrop, Bottrop
| |
Collapse
|
209
|
Pecks U, Caspers R, Sosnowsky K, Freerksen N, Maass N, Huppertz B, Rath W. Untersuchungen des maternalen und fetalen Serumlipidprofils und des oxidierten ‚Low Density‘ Lipoproteins im plazentaren Gewebe bei Präeklampsie und normotensiven Schwangerschaften. Z Geburtshilfe Neonatol 2012; 216:220-5. [DOI: 10.1055/s-0032-1323793] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- U. Pecks
- Frauenklinik für Gynäkologie und Geburtsmedizin des Universitätsklinikums der RWTH Aachen
| | - R. Caspers
- Frauenklinik für Gynäkologie und Geburtsmedizin des Universitätsklinikums der RWTH Aachen
| | - K. Sosnowsky
- Frauenklinik für Gynäkologie und Geburtsmedizin des Universitätsklinikums der RWTH Aachen
| | - N. Freerksen
- Frauenklinik für Gynäkologie und Geburtsmedizin des Universitätsklinikums der RWTH Aachen
| | - N. Maass
- Frauenklinik für Gynäkologie und Geburtsmedizin des Universitätsklinikums der RWTH Aachen
| | - B. Huppertz
- Institut für Zellbiologie, Histologie und Embryologie, Medizinische Universität Graz, Österreich
| | - W. Rath
- Gynäkologie und Geburtshilfe, Medizinische Fakultät des Universitätsklinikums der RWTH Aachen
| |
Collapse
|
210
|
Abstract
OBJECTIVE Case report of a 35-year-old gravida 3, para 2, at 40 + 6 weeks with massive respiratory dysfunction with need of oxygenation, requiring cesarean section. CASE REPORT Postpartum investigations revealed pathological cardiomegaly with left ventricular failure (NYHAIV). Cardiac biopsy diagnosed postpartum dilatative cardiomyopathy. Despite medication with bromocriptine and levosimendan, cardiac function continued to decrease, requiring surgical intervention and implantation of an intracorporal, left ventricular assist device. Following surgery, cardiac function progressively improved and stabilized. OBJECTIVE Peripartum cardiomyopathy (PPCM) is a rare, pregnancy-induced disease and requires an interdisciplinary approach for diagnostics and therapeutical treatment.
Collapse
Affiliation(s)
- Nele Freerksen
- Department of Obstetrics and Gynecology, University Hospital Aachen, Aachen, Germany.
| | | | | | | | | |
Collapse
|
211
|
De Jong R, Sonke G, Maass N, Mansouri K, Cirri L, Shi P, Hamid O, Mariani G. Fulvestrant (FUL) Plus Enzastaurin (ENZA) vs FUL Plus Placebo (PBO) in Aromatase Inhibitor (AI)-Resistant Metastatic Breast Cancer (MBC): A Randomized, Double-Blind, Phase 2 Trial. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32903-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
212
|
Lühr I, Friedl A, Overath T, Tholey A, Kunze T, Hilpert F, Sebens S, Arnold N, Rösel F, Oberg HH, Maass N, Mundhenke C, Jonat W, Bauer M. Mammary fibroblasts regulate morphogenesis of normal and tumorigenic breast epithelial cells by mechanical and paracrine signals. Cancer Lett 2012; 325:175-88. [PMID: 22776560 DOI: 10.1016/j.canlet.2012.06.014] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2012] [Revised: 06/27/2012] [Accepted: 06/30/2012] [Indexed: 01/24/2023]
Abstract
Stromal factors play a critical role in the development of the mammary gland. Using a three dimensional-coculture model we demonstrate a significant role for stromal fibroblasts in the regulation of normal mammary epithelial morphogenesis and the control of tumor growth. Both soluble factors secreted by fibroblasts and fibroblast-derived modifications of the matrix compliance contribute to the regulation of epithelial cell morphogenesis. Readjustment of matrix tension by fibroblasts can even induce a phenotypic reversion of breast carcinoma cells. These data offer a basis to develop new strategies for the normalization of the tumor stroma as an innovative target in cancer therapy.
Collapse
Affiliation(s)
- Inke Lühr
- Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Christian-Albrechts University, Kiel, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
213
|
Kolberg HC, Lüftner D, Lux MP, Maass N, Schütz F, Fasching PA, Fehm T, Janni W, Kümmel S. Breast Cancer 2012 - New Aspects. Geburtshilfe Frauenheilkd 2012; 72:602-615. [PMID: 25324576 PMCID: PMC4168404 DOI: 10.1055/s-0032-1315131] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2012] [Revised: 06/23/2012] [Accepted: 06/23/2012] [Indexed: 12/31/2022] Open
Abstract
Treatment options as well as the characteristics for therapeutic decisions in patients with primary and advanced breast cancer are increasing in number and variety. New targeted therapies in combination with established chemotherapy schemes are broadening the spectrum, however potentially promising combinations do not always achieve a better result. New data from the field of pharmacogenomics point to prognostic and predictive factors that take not only the properties of the tumour but also inherited genetic properties of the patient into consideration. Current therapeutic decision-making is thus based on a combination of classical clinical and modern molecular biomarkers. Also health-economic aspects are more frequently being taken into consideration so that health-economic considerations may also play a part. This review is based on information from the recent annual congresses. The latest of these are the 34th San Antonio Breast Cancer Symposium 2011 and the ASCO Annual Meeting 2012. Among their highlights are the clinically significant results from the CLEOPATRA, BOLERO-2, EMILIA and SWOG S0226 trials on the therapy for metastatic breast cancer as well as further state-of-the-art data on the adjuvant use of bisphosphonates within the framework of the ABCSG-12, ZO-FAST, NSABP-B34 and GAIN trials.
Collapse
Affiliation(s)
- H.-C. Kolberg
- Klinik für Gynäkologie und Geburtshilfe, Marienhospital Bottrop, Bottrop
| | - D. Lüftner
- Medizinische Klinik und Poliklinik II, Campus Charité Mitte, Berlin
| | - M. P. Lux
- Frauenklinik, Universitätsklinikum Erlangen, Erlangen
| | - N. Maass
- Department of Gynecology and Obstetrics, University Hospital Aachen
| | - F. Schütz
- Frauenklinik, Universitätsklinikum Heidelberg, Heidelberg
| | - P. A. Fasching
- Department of Gynecology and Obstetrics, University Hospital Erlangen, Erlangen
| | - T. Fehm
- Department of Obstetrics and Gynecology, University Tübingen, Tübingen
| | - W. Janni
- Frauenklinik, Klinikum der Heinrich-Heine-Universität Düsseldorf, Düsseldorf
| | - S. Kümmel
- Klinik für Senologie, Kliniken Essen-Mitte, Essen
| |
Collapse
|
214
|
Serno J, Zeppernick F, Jäkel J, Schrading S, Maass N, Meinhold-Heerlein I, Bauerschlag DO. Primary pulmonary choriocarcinoma: case report and review of the literature. Gynecol Obstet Invest 2012; 74:171-6. [PMID: 22738859 DOI: 10.1159/000336784] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2011] [Accepted: 01/24/2012] [Indexed: 11/19/2022]
Abstract
Primary pulmonary choriocarcinoma is a rare disease with only 31 reported cases in the literature so far. Here, we summarize all published cases, including a recent case of our own clinic. Patients usually presented with symptoms like dyspnea, cough, chest pain, weight loss or hemoptysis. In some cases, the nodule in the lung was found in a routine check-up in asymptomatic patients. In the present case, the patient presented to our clinic because of a positive urine pregnancy test despite taking oral contraceptives. Patients in the analyzed cases were either treated with surgery, chemotherapy, radiotherapy or best supportive care. In the present case, a complete resection of the tumor was possible and the patient has not had any signs of recurrence so far. When looking at the published cases and corresponding outcomes, a slight tendency toward a complete resection followed by chemotherapy or close follow-up examinations seems to give the patients the best survival chances. Nevertheless, the overall prognosis of primary pulmonary choriocarinoma is poor and the 5-year survival rate is below 5%.
Collapse
Affiliation(s)
- Julia Serno
- Department of Obstetrics and Gynecology, University Medical Center Aachen, Aachen, Germany.
| | | | | | | | | | | | | |
Collapse
|
215
|
Maass N, Harbeck N, Mundhenke C, Lerchenmuller CA, Barinoff J, Lueck HJ, Ettl J, Aktas B, Kuemmel S, Roesel S, Wagner S, Müller L, Bischoff J, Luebbe K, Schwedler K, Schmidt M, Bauerschlag D, Nekljudova V, Loibl S, Von Minckwitz G. Everolimus (RAD) as treatment in breast cancer patients with bone metastases only: Results of the phase II RADAR study. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.556] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
556 Background: RAD001 is an orally bioavailable rapamycin ester analogue, which acts by selectively inhibiting mTOR (mammalian target of rapamycin), a key player in downstream signaling of different pathways. In vitro, RAD stops formation and activity of osteoclasts. Treating progressive bone metastases in breast cancer (bc) with RAD seems reasonable. Methods: We evaluated RAD in a placebo-controlled, phase II, randomized discontinuation study in bc patients (pts) with bone metastases only. Pts were eligible if they had HER2-negative, hormone-receptor (HR)-positive or –negative bc, with a maximum of 2 previous lines of endocrine therapy (ET) and 1 previous line of chemotherapy (CT). All pts received zoledronate and pts with HR-positive bc could receive ET. All pts started with RAD during a run-in phase of 8 weeks. Pts with stable disease were randomized to RAD or placebo; pts with response continued with RAD and pts with progression went off study. Primary outcome was time to progression (TTP) in pts being stable on 8 weeks of RAD. It was assumed that placebo would obtain a median TTP of 8 weeks which would be increased to 16 weeks, thus requiring 76 randomized pts. It was expected that 70% of all pts would have stable disease after the run-in phase. Overall, 110 pts were needed. Due to slow recruitment and dysbalance between randomized and discontinued pts, recruitment stopped in 12/ 2010. Results: From 11/06 until 12/10, 89 pts were enrolled. Median age was 59.5 years. 93% had HR-positive disease. 15% had prior chemotherapy; 58% had prior ET for metastases. 1/3 received concomitant ET. Three pts did not start therapy, 41 discontinued during run-in phase, 32 due to progression. Six continued as responder. 39 pts with SD after run in phase were randomized to RAD or placebo. Twenty-seven stopped due to progression; 9 discontinued due to AE, 4 are still on treatment. 15 pts had 20 serious adverse events; 1 hyperglycemia and one alveolitis. The TTP in patients with RAD was 8.5 months vs. 2.9 months with placebo (HR: 0.559; 95% CI [0.284-1.10] p=0.092. Conclusions: Pts with bone metastases only had a longer TTP on RAD compared to pts on placebo. Overall 7/89 showed a sustained response on RAD + zoledronate ± ET.
Collapse
Affiliation(s)
| | - Nadia Harbeck
- Breast Center, Dept of OB&GYN, University of Munich, Munich, Germany
| | | | | | - Jana Barinoff
- Dr.-Horst-Schmidt-Kliniken, Klinik f. Gyn. und gyn. Onkologie, Wiesbaden, Germany
| | | | - Johannes Ettl
- Department of Obstetrics and Gynecology, Technical University Munich, Munich, Germany
| | - Bahriye Aktas
- Universitätsklinikum Essen, Klinik für Frauenheilkunde und Geburtshilfe, Essen, Germany
| | | | - Siegfried Roesel
- Onkologische Schwerpunktpraxis Guetersloh/Onkodok GmbH, Klinische Studien, Guetersloh, Germany
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
216
|
Mundhenke C, Schem C, Bauerschlag DO, Weigel MT, Wenners AS, Schaefer FW, Tiemann K, Hanson S, Muth M, May C, Jonat W, Maass N. Clinical and safety data of a phase I/II trial with imatinib and vinorelbine for patients with metastatic breast cancer (MBC). J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.e13503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e13503 Background: Imatinib is a tyrosine kinase inhibitor of bcr-abl, PDGF-R, SCF, c-Kit and abl. In solid tumors it inhibits proliferation and facilitates higher intratumoral cytotoxic drug concentrations. Vinorelbine has good tolerability and efficacy in MBC. This study evaluates the combination of imatinib and vinorelbine. Methods: In aprospective open-label, phase I/II trial 400 mg imatinib p.o. daily (amended from 600 mg) was combined with an escalating dose of vinorelbine i.v. weekly in four dose levels with 10, 15, 20, 25 mg/m² (each n ≥ 5) for pats. with MBC (which express PDGF-R-α and/or -β and/or c-kit). The last pat. of a level was treated > 28 days, before enrolment for the next dose level started. Study endpoints were feasibility and tolerability, incidence of hematological and non-hematological toxicity and clinical efficacy (data cut: 18/11/2011). A translational subprotocol is ongoing. 33 pats. have been enrolled; all dose levels have been fully recruited. 1 patient is still on study medication. Results: 32 pats. are evaluable (ITT population). 11 pats. went off study early (progressive disease, toxicity and withdrawal of consent). 22 pats. were on study >28 days (“ITT>28”). Within the ITT population the response rate (complete (CR) and partial response (PR)) was 9.4% (n=3), the clinical benefit rate CBR (CR+PR+stable disease) 50% (n=16), median time to progression (TTP) 155 days. 21.3% were on study medication >6 months, 15.2% > 12 months (mean 133 days, 15-617 days). Within “ITT>28,” the response rate was 13.6%, CBR 72.7% and median TTP 176 days. Toxicities (ITT population): 21.6% severe leukopenia, 9.1% severe neutropenia (with 1 febrile neutropenia), 1 case of bowel perforation, 36% diarrhea (3% severe), 84.8% nausea (severe 15.2%), 48.5% vomiting (severe 9.1%), 27.3% infections (severe 6.1%), 12.1% periph. neuropathy (severe 9.1%) and 36.4% dyspnea (3% severe). 1 patient on study medication died (non drug related). Conclusions: The combination of imatinib and vinorelbine in MBC appeared to be feasible and tolerable. A CBR of 50% (ITT) in pre-treated pats. proves the efficacy of this combination. Although toxicities were frequent, they appeared to be manageable.
Collapse
Affiliation(s)
| | | | - Dirk Olaf Bauerschlag
- Department of Obstetrics and Gynecology, University Hospital Aachen, Aachen, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
217
|
Pecks U, Tillmann D, Ernst S, Maass N, Meinhold-Heerlein I. Anti-oxidized low-density lipoprotein (oxLDL) antibody levels are not related to increasing circulating oxLDL concentrations during the course of pregnancy. Am J Reprod Immunol 2012; 68:345-52. [PMID: 22594315 DOI: 10.1111/j.1600-0897.2012.01157.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2012] [Revised: 04/04/2012] [Accepted: 04/16/2012] [Indexed: 11/28/2022] Open
Abstract
PROBLEM To address the question of whether the high levels of oxidative modified low-density lipoproteins (oxLDL) in pregnancy are opposed by an appropriate humoral autoimmune response providing anti-oxLDL autoantibodies in maternal serum of healthy women throughout gestation. METHOD OF STUDY Blood was taken from 33 patients at four different time points from early to late gestation and post-partum. OxLDL and anti-oxLDL concentrations were measured by enzyme-linked immunosorbent assays. ANOVA was used for statistical evaluations followed by post hoc test with Bonferoni adjustment. RESULTS Oxidized Low Density Lipoprotein concentrations increased while anti-oxLDL levels decreased significantly from early to late gestation. OxLDL was strongly positively correlated with LDL concentration and mildly negatively associated with anti-oxLDL levels. Estimating the status of oxidation by calculating oxLDL/LDL ratio revealed decreasing values with ongoing pregnancy. Multivariate analysis showed that anti-oxLDL levels were dependent on gestational age but neither on oxLDL levels nor on the oxLDL/LDL ratio. CONCLUSIONS The results indicate that normal pregnancy is a well-balanced state of oxidative and anti-oxidative processes. However, we could not confirm a dependence of anti-oxLDL autoantibodies on oxLDL concentration. Whether or not the humoral immune system is involved in oxidative defence remains to be elucidated.
Collapse
Affiliation(s)
- Ulrich Pecks
- Department of Obstetrics and Gynecology, University Hospital of the RWTH Aachen, Aachen, Germany.
| | | | | | | | | |
Collapse
|
218
|
Schrading S, Strobel K, Maass N, Naami A, Kuhl C. Inzidenz und Bedeutung von in der MRT und mittels MR-gesteuerter Vakuumbiopsie diagnostizierter flacher epithelialer Atypien (FEA). ROFO-FORTSCHR RONTG 2012. [DOI: 10.1055/s-0032-1311302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
219
|
Sosnowsky K, Caspers R, Maass N, Huppertz B, Rath W, Pecks U. Die Anreicherung von Oxidiertem ‚Low Density Lipoprotein' (oxLDL) und Expression des'lectin-like oxLD' Receptors (LOX-1) in der Plazenta bei Präeklampsia und gesunden Kontrollen. Z Geburtshilfe Neonatol 2012. [DOI: 10.1055/s-0032-1309126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
220
|
Caspers R, Sosnowsky K, Bauerschlag DO, Maass N, Huppertz B, Rath W, Pecks U. Die Anreicherung von voll und minimal oxidiertem ‚Low Density Lipoprotei' im plazentaren Gewebe bei intrauteriner Wachstumsrestriktion (IUGR) und gesunden Kontrollen. Z Geburtshilfe Neonatol 2012. [DOI: 10.1055/s-0032-1309127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
221
|
Pecks U, Brieger M, Schiessl B, Bauerschlag DO, Piroth D, Bruno B, Fitzner C, Orlikowsky T, Maass N, Rath W. Maternal and fetal cord blood lipids in intrauterine growth restriction. J Perinat Med 2012; 40:287-96. [PMID: 22505508 DOI: 10.1515/jpm.2011.135] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/08/2011] [Accepted: 11/21/2011] [Indexed: 11/15/2022]
Abstract
AIM Small for gestational age neonates (SGA) could be subdivided into two groups according to the underlying causes leading to low birth weight. Intrauterine growth restriction (IUGR) is a pathologic condition with diminished growth velocity and fetal compromised well-being, while non-growth restricted SGA neonates are constitutionally (genetically determined) small. Antenatal sonographic measurements are used to differentiate these two subgroups. Maternal metabolic changes contribute to the pathogenesis of IUGR. A disturbed lipid metabolism and cholesterol supply might affect the fetus, with consequences for fetal programming of cardiovascular diseases. We evaluated fetal serum lipids and hypothesized a more atherogenic lipoprotein profile in IUGR fetuses. METHODS Umbilical cord serum lipids and oxidative modified, low-density lipoprotein (oxLDL) concentrations were measured by colorimetric enzymatic measurements, or by ELISA. Values of IUGR (n=36) and constitutionally small for gestational age neonates (SGA, n=22) were compared with those of healthy, adequate for gestational age, born neonates (CN, n=97). SAS-statistic software was used and two-way ANOVA was adjusted for gestational age at delivery. RESULTS Fetal high-density lipoprotein cholesterol (HDL-C) and total cholesterol (TC) concentrations were found to be lower in the IUGR compared to the CN and SGA groups (HDL-C: P<0.001, TC: P<0.01). Atherogenic indices, including the oxLDL/LDL-C ratio, were increased in the IUGR compared to the CN group (oxLDL/LDL-C ratio: P<0.001). CONCLUSION Our results support the hypothesis of a disturbed cholesterol supply in IUGR fetuses. Born SGA has been shown to be a risk factor for developing cardiovascular disease later in life. Since HDL-C has anti-inflammatory properties, a reduced HDL-C during fetal development, and an increase in atherogenic indices, might provide a link to this observation in IUGR fetuses.
Collapse
Affiliation(s)
- Ulrich Pecks
- Department of Obstetrics and Gynecology of the University Hospital of the RWTH Aachen, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
222
|
Weigel MT, Krämer J, Schem C, Wenners A, Alkatout I, Jonat W, Maass N, Mundhenke C. Differential expression of MMP-2, MMP-9 and PCNA in endometriosis and endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol 2012; 160:74-8. [DOI: 10.1016/j.ejogrb.2011.09.040] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2011] [Revised: 08/12/2011] [Accepted: 09/28/2011] [Indexed: 10/15/2022]
|
223
|
Najjari L, Blum R, Hennemann J, Maass N, Kirschner-Hermanns R. [Using contrast inversion to extend the diagnostic value of perineal ultrasound for urethral and paraurethral pathologies]. Ultraschall Med 2011; 32 Suppl 2:E182-E190. [PMID: 22194048 DOI: 10.1055/s-0031-1281792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
PURPOSE The aim of our study was to show how using contrast inversion extends the diagnostic value of perineal ultrasound, in particular with regard to paraurethral pathologies. MATERIALS AND METHODS To assess the practical value of contrast inversion in the daily routine, 42 women with urinary incontinence underwent perineal ultrasound examination. Pictures were converted to contrast inversion and then checked for the visibility of sonographic reference points for urogynecological measurements (urethra, meatus urethrae internus, vesical base) by two independent evaluators both in B-mode and contrast inversion. Visibility was compared using a coefficient of agreement. The results were then tested for significance. In addition, in our clinical routine we detected several paraurethral pathologies (e. g. paraurethral abscess, glandula paraurethralis, urethral diverticulum), each being presented in B-mode and contrast inversion. RESULTS There was no significant difference between contrast inversion and B-mode with regard to the reproducibility of visibility of the three sonographic reference points. Contrast inversion was superior for depicting paraurethral pathologies and postoperative anatomical findings. CONCLUSION With respect to routine evaluation, the two modes do not reveal any significant difference. For the sonographic evaluation of paraurethral pathologies, contrast inversion provides better contour sharpness than B-mode, suggesting a higher diagnostic value for ambiguous anatomical settings. The nature of contrast inversion nevertheless facilitates misinterpretations and requires frequent comparison with B-mode pictures. In conclusion, we propose contrast inversion as an initial screen and a refinement to established diagnostic methods, such as MRI and voiding cysturethrography, not as their substitute.
Collapse
Affiliation(s)
- L Najjari
- Frauenklinik für Gynäkologie und Geburtsmedizin, Universitätsklinikum RWTH Aachen, Aachen.
| | | | | | | | | |
Collapse
|
224
|
Najjari L, Hennemann J, Maass N, Kirschner-Hermanns RK. [Perineal ultrasound for diagnostics of male stress incontinence: comparative study on the application of urogynecological standards for men and women]. Urologe A 2011; 51:384-9. [PMID: 22113548 DOI: 10.1007/s00120-011-2756-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
BACKGROUND The diagnostic options for persistent urinary incontinence following prostatectomy are limited despite incidence numbers of up to 40%. Perineal ultrasound, which is already well established in urogynecology to quantify urethral mobility, can also be used for the diagnostics of incontinence in men. The present study investigated whether there is a difference in reproducibility concerning the quantification of urethral mobility between men and women. MATERIAL AND METHODS A total of 27 men and 27 women aged 65-85 years participated in the study. All underwent perineal ultrasound examination following standardized criteria under the three conditions of rest, contraction and a Valsalva maneuvre. Ultrasound images were taken under each condition and given to two independent examiners for evaluation. For all conditions it was recorded which of the three reference points for the quantification of urethral mobility, the urethra, internal urethral meatus and the base of the urinary bladder, could be assessed. The results were compared by means of a coefficient of agreement (p0) and the difference of the results between the two groups was validated for statistical significance using Student's t-test. RESULTS At a t-value of 1.58 (p=0.154) there were no significant differences in the reproducibility in visualizing the three sonographic reference points, the urethra, internal urethral meatus and the base of the urinary bladder, between men and women. CONCLUSIONS Using perineal ultrasound for quantification of urethral mobility in the diagnostics of incontinence in men after prostatectomy is just as reproducible in men as in women. For both sexes the technique is comfortable and pain-free due to the non-invasive nature. Perineal ultrasound is a cheap, non-invasive and reproducible diagnostic procedure which can be recommended for the evaluation of incontinence and the selection of a suitable surgical procedure also in men.
Collapse
Affiliation(s)
- L Najjari
- Klinik für Gynäkologie und Geburtshilfe, Uniklinik Aachen, Kapuzinergasse 7, 52068 Aachen, Deutschland.
| | | | | | | |
Collapse
|
225
|
Kümmel S, Kolberg H, Lüftner D, Lux M, Maass N, Schütz F, Fasching P, Fehm T, Janni W. Mammakarzinom 2011 – Neue Aspekte. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0031-1280313] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022] Open
|
226
|
Pecks U, Schiessl B, Bauerschlag D, Maass N, Rath W. Evaluating fetal cord blood lipids and oxidized LDL status in intrauterine growth restriction and preeclampsia. Z Geburtshilfe Neonatol 2011. [DOI: 10.1055/s-0031-1293443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
227
|
Pecks U, Schiessl B, Fitzner C, Bauerschlag DO, Rath W, Maass N. Evaluation der Serumlipoproteinkonzentrationen und des oxidativ modifizierten LDLs von Schwangeren und deren Feten bei intrauteriner Wachtsumsrestriktion und Präeklampsie. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0031-1286408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
228
|
Bauerschlag DO, Bräutigam K, Pecks U, Meinhold-Heerlein I, Maass N. Progressionsfreies Überleben im Ovarialkarzinom zeigt sich in epigenetischen DNA Methylierungsprofilen. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0031-1286475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
229
|
Meinhold-Heerlein I, Bauerschlag D, Bräutigam K, Maass N. Identifizierung neuer molekularer Marker des serösen Ovarialkarzinoms mit dem Potential als therapeutische Targets sowie als Serummarker zur Früherkennung. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0031-1286496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
230
|
Mundhenke C, Schem C, Bauerschlag D, Weigel M, Tiemann K, Maass N, Jonat W. Imatinib Mesylat in Kombination mit Vinorelbine bei metastasiertem Mammakarzinom – Ein erster Bericht zur Durchführung der Phase I/II Studie. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0031-1286455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
231
|
von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, de Jongh FE, Baumann KH, Bischoff J, Harbeck N, Lück HJ, Maass N, Zielinski C, Andersson M, Stein RC, Nekljudova V, Loibl S. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer 2011; 47:2273-81. [PMID: 21741829 DOI: 10.1016/j.ejca.2011.06.021] [Citation(s) in RCA: 131] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2011] [Revised: 06/07/2011] [Accepted: 06/07/2011] [Indexed: 12/12/2022]
Abstract
BACKGROUND Continuation of trastuzumab plus capecitabine (XH) showed a significantly improved overall response rate and time to progression compared with capecitabine (X) alone in women with HER2-positive breast cancer progressing during trastuzumab treatment. Here, we report the final analysis on overall survival. PATIENTS AND METHODS Patients with HER2-positive, advanced breast cancer who progressed during treatment with trastuzumab with or without 1st-line metastatic chemotherapy were prospectively randomised to X (2500mg/m(2) on days 1-14, q3w) or XH (6 (8)mg/kg, q3w). Overall survival was a pre-specified secondary end-point. RESULTS Median follow-up at June 2010 was 20.7months. Fifty nine of 74 and 60 of 77 patients died in the X and XH arm, respectively. Median overall survival was 20.6 and 24.9months with X and XH, respectively (HR=0.94 [0.65-1.35]; p=0.73). Performance status and metastatic site were independent prognosticators for overall survival. No difference between treatment arms was observed for patients who achieved clinical response or clinical benefit, respectively. Patients who continued/restarted anti-HER2 treatment (trastuzumab or lapatinib) after 2nd progression (N=52) had a post-progression survival of 18.8 compared with 13.3months for those who did not receive 3rd line treatment with anti-HER2 agents (N=88) (HR 0.63; p=0.02). CONCLUSIONS Final overall survival analysis of the GBG-26 study did not demonstrate a significant survival benefit for treatment beyond progression with trastuzumab. However, in a post-hoc analysis, patients receiving anti-HER2 treatment as 3rd line therapy showed a better post-progression survival than those not receiving this targeted treatment.
Collapse
Affiliation(s)
- Gunter von Minckwitz
- German Breast Group, GBG ForschungsGmbH, Martin-Behaim Str. 12, 63263 Neu-Isenburg, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
232
|
Erhart W, Alkasi Ö, Brunke G, Wegener F, Maass N, Arnold N, Arlt A, Meinhold-Heerlein I. Induction of human β-defensins and psoriasin in vulvovaginal human papillomavirus-associated lesions. J Infect Dis 2011; 204:391-9. [PMID: 21730203 DOI: 10.1093/infdis/jir079] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
BACKGROUND Infections with a low-risk type of human papillomavirus (HPV) may lead to genital warts. HPV targets the basal cell layer of epithelial cells. The first line of defense is the innate immune system, which provides nonspecific protection against a variety of pathogens. The antimicrobial peptides (AMPs) α- and β-defensins, cathelicidins, psoriasin, and RNase7 are central mediators. METHODS The expression of various α- and β-defensins, cathelicidin LL-37, psoriasin, and RNase7 was studied in biopsy samples from 35 patients with genital warts and 25 healthy women using quantitative real-time polymerase chain reaction and immunohistochemical analysis. RESULTS We found a significantly higher expression of the β-defensins hBD-1 (P = .03), hBD-2 (P < 0.01), and hBD-3 (P < .001), and psoriasin (P = .001) in condylomata acuminata, compared with normal controls. The RNA and protein levels of RNase7 did not differ between infected and uninfected samples (P = .55). The α-defensins HNP 1-3, HD5, and HD6 and the cathelicidin LL-37 were scarcely detectable in normal and infected tissue. CONCLUSIONS The differing expression of AMPs in HPV-infected, compared with noninfected, vulvovaginal biopsy samples suggests that these peptides are important in the local immune response. Curiously, hBD-1 shows a significant induction whereas RNase7 does not, which suggests differing regulation of AMPs over the course of bacterial and viral infections.
Collapse
Affiliation(s)
- W Erhart
- Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Kiel, Germany
| | | | | | | | | | | | | | | |
Collapse
|
233
|
Untch M, Gerber B, Möbus V, Schneeweiss A, Thomssen C, Minckwitz GV, Beckmann M, Blohmer JU, Costa SD, Diedrich K, Diel I, Eiermann W, Friese K, Harbeck N, Hilfrich J, Jackisch C, Janni W, Jänicke F, Jonat W, Kaufmann M, Kiechle M, Köhler U, Kreienberg R, Maass N, Marschner N, Nitz U, Scharl A, Wallwiener D. St.-Gallen-Konferenz 2011 zum primären Mammakarzinom. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0030-1271133] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
234
|
Bauerschlag DO, Ammerpohl O, Bräutigam K, Schem C, Lin Q, Weigel MT, Hilpert F, Arnold N, Maass N, Meinhold-Heerlein I, Wagner W. Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles. Oncology 2011; 80:12-20. [PMID: 21577013 DOI: 10.1159/000327746] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2010] [Accepted: 02/18/2011] [Indexed: 12/23/2022]
Abstract
OBJECTIVE Many patients with ovarian cancer disease relapse within 6 months after adjuvant chemotherapy, with a limited prognosis. Epigenetic modifications have been shown to play an important role in tumor development and formation. Therefore, global analysis of DNA methylation patterns might reveal specific CpG sites that correlate with progression-free interval (PFI) after therapy. METHODS Twenty samples of advanced ovarian cancer with a predominantly serous papillary histological subtype were subjected to DNA methylation profiling. Illumina HumanMethylation27 BeadChip technology was used for simultaneous analysis of 27,578 CpG sites in >14,000 genes. RESULTS Differential DNA methylation of various cytosines correlated with PFI. However, this becomes only significant by classification according to PFI with a cutoff of >28 months. Longer survival was associated with hypomethylation at specific CpG sites (e.g. GREB1, TGIF and TOB1) and hypermethylation in other genes (e.g. TMCO5, PTPRN and GUCY2C). Gene ontology analysis revealed that differentially methylated genes were significantly overrepresented in the categories telomere organization, mesoderm development and immune regulation. CONCLUSION Epigenetic modifications at specific CpG sites correlate with PFI in ovarian cancer. Therefore, such analysis might be of prognostic value.
Collapse
Affiliation(s)
- Dirk O Bauerschlag
- Department of Gynecology, University Medical Center Aachen, RWTH, Aachen, Germany.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
235
|
Bauerschlag DO, Schem C, Weigel MT, Von Kaisenberg C, Strauss A, Bauknecht T, Maass N, Meinhold-Heerlein I. The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer. J Cancer Res Clin Oncol 2011; 136:79-88. [PMID: 19609560 DOI: 10.1007/s00432-009-0639-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2009] [Accepted: 06/23/2009] [Indexed: 02/07/2023]
Abstract
INTRODUCTION In advanced ovarian cancers (OCs), p53 mutations are frequently observed. The objective of this study was to explore the value of the p53 mutational status, using four different techniques, in advanced OC patients as a predictive marker for responsiveness to platinum-based chemotherapy. METHODS One hundred and four, mostly serous papillary OC specimens were analyzed, of which all received a platinum containing chemotherapy after optimal cyto-reductive surgery. To verify the p53 mutational status, immunohistochemical staining with monoclonal antibodies, functional yeast assay (FASAY), single-strand conformation polymorphism analysis (SSCP) and genomic sequencing was performed in parallel. RESULTS Out of ten OC patients [2 low malignant potential (LMP)/8 G1] only two had a mutant p53, whereas eight showed a wild-type p53. 40 out of 63 (G2/3) patients with G2/3 OC showed mutant p53 and 23 patients showed a wild-type pattern. p53 status was significantly different between these two groups (LMP/G1 vs. G2/3) (P = 0.015). A progressive disease after chemotherapy completion was noted in 35.6% of the patients (26 out of 73); in 69.2%, a mutated p53 and in 30.8%, a wild-type p53 was found. Nine (12.3%) patients showed a complete response at the end of the first-line chemotherapy. Out of these nine patients five had a mutated and four a wild-type p53. A partial response was observed in nine (12.3%) patients of whom four had a mutated p53. With respect to response to first-line chemotherapy (six cycles of platinum containing regimen), the p53 status was not predictive; no statistical significance regarding the p53 mutational status was observed when the two extreme groups PD versus PR/CR were compared (P > 0.05). CONCLUSION In this study, the p53 mutational status was not predictive for responsiveness to platinum-based chemotherapy; but p53 was significantly more frequently mutated in poorly differentiated OCs.
Collapse
Affiliation(s)
- Dirk O Bauerschlag
- Department of Gynecology and Obstetrics University Hospital, Universitätsklinikum RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
236
|
Wölfler MM, Meinhold-Heerlein IM, Söhngen L, Rath W, Knüchel R, Neulen J, Maass N, Henkel C. Two-dimensional gel electrophoresis in peritoneal fluid samples identifies differential protein regulation in patients suffering from peritoneal or ovarian endometriosis. Fertil Steril 2011; 95:2764-8. [PMID: 21497343 DOI: 10.1016/j.fertnstert.2011.03.061] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2010] [Revised: 03/06/2011] [Accepted: 03/21/2011] [Indexed: 11/27/2022]
Abstract
Endometriosis is determined by local and systemic proinflammatory dysregulation and therefore differential protein expression in peritoneal fluid (PF). Of highest interest is lesion formation and the establishment and persistence of endometriosis. In this study we analyzed well-characterized PF samples of patients with ovarian or peritoneal endometriosis and compared them to control samples. We found 11 proteins differentially regulated, of which some might play a key role in the pathogenesis of endometriosis.
Collapse
Affiliation(s)
- Monika M Wölfler
- Department of Obstetrics and Gynecology, Medical Faculty of RWTH Aachen University, Aachen, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
237
|
Kirschner-Hermanns R, Najjari L, Brehmer B, Blum R, Zeuch V, Maass N, Heidenreich A. Two- and three-/four dimensional perineal ultrasonography in men with urinary incontinence after radical prostatectomy. BJU Int 2011; 109:46-51. [PMID: 21489119 DOI: 10.1111/j.1464-410x.2011.10191.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
238
|
Wölfler M, Stadermann M, Rath W, Klein P, Maass N, Rimbach S. Anamnestisches Screening bei symptomatischen Patientinnen mit und ohne Endometriose. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0030-1250677] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
239
|
Breidenbach M, Schmidt T, Volkmer A, Rath W, Fleisch M, Maass N, Porn A, Hess A, Janni W, Rein D. Identifikation geeigneter Zielstrukturen zur Entwicklung einer zielgerichteten Systemtherapie der Endometriose. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0030-1250768] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
240
|
Pecks U, Maass N, Neulen J. Oocyte donation: a risk factor for pregnancy-induced hypertension: a meta-analysis and case series. Dtsch Arztebl Int 2011; 108:23-31. [PMID: 21285999 DOI: 10.3238/arztebl.2011.0023] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/25/2010] [Accepted: 09/23/2010] [Indexed: 01/02/2023]
Abstract
BACKGROUND In 2008 and 2009, the authors saw in their institution three women who had undergone oocyte donation and went on to develop severe de novo hypertension before the 26(th) week of gestation, with values above 180/110 mm Hg. Pregnancy was prematurely terminated in these cases because of the acute threat to the mother's life, and none of the three neonates survived. Five further cases with better outcomes were found to have occurred from 2006 to 2010. On the basis of this experience, the authors performed a meta-analysis to determine whether oocyte donation elevates the risk of pregnancy-induced hypertension (PIH). The cases are discussed in detail. METHODS Systematic review of the literature on PIH after oocyte donation, with meta-analysis and calculation of an odds ratio. We also provide a retrospective chart review of our own case series. RESULTS 28 publications were evaluated. The overall rate of PIH in a total of 2308 deliveries after oocyte donation was 22.6%. With the aid of data from 11 studies, the course of pregnancy in a total of 644 oocyte recipients was compared to that in a control group of 2320 women who were not oocyte recipients. The calculated odds ratio for PIH after oocyte donation, compared to conventional reproductive therapy, was 2.57 (95% CI, 1.91-3.47), while the calculated odds ratio for PIH after oocyte donation, compared to other women in the control group, was 6.60 (95% CI, 4.55-9.57). CONCLUSION The data reveal that oocyte donation confers a considerable risk that the recipient will develop PIH. The very early and severe cases of preeclampsia that we report here are rather atypical; similar cases may have occurred elsewhere without finding their way into the relevant literature. The authors recommend close surveillance of pregnancies following allogenic oocyte transplantation by physicians with special expertise in prenatal medicine.
Collapse
Affiliation(s)
- Ulrich Pecks
- Frauenklinik für Gynäkologie und Geburtsmedizin, Universitätsklinikum der RWTH Aachen, Pauwelsst. 30, 52057 Aachen, Germany
| | | | | |
Collapse
|
241
|
Pecks U, Caspers R, Schiessl B, Bauerschlag D, Piroth D, Maass N, Rath W. The evaluation of the oxidative state of low-density lipoproteins in intrauterine growth restriction and preeclampsia. Hypertens Pregnancy 2011; 31:156-65. [PMID: 21250891 DOI: 10.3109/10641955.2010.544805] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
OBJECTIVE To evaluate the oxidative state of lipoproteins in pregnancies complicated by intrauterine growth restriction (IUGR) in comparison to preeclampsia (PE) and healthy pregnant control subjects (CN). METHODS Maternal serum of 20 PE, 29 IUGR, and 29 gestational age-matched CN were analyzed. Total cholesterol (TC), low-density lipoprotein (LDL)-bound cholesterol (LDL-C), and oxidized LDL (oxLDL) concentration were measured once between 25 and 34 weeks of gestation. Statistical estimates were performed by Student's t-test. RESULTS Serum concentrations of LDL-C and TC were significantly reduced in IUGR [LDL-C: CN - mean = 146 mg/dL, SD = ± 40.1; IUGR - mean = 102 mg/dL, SD = ± 27.3 (p < 0.0001); PE - mean = 130 mg/dL, SD = 38.8 mg/dL; TC: CN - mean = 259/dL, SD = ± 46.8; IUGR - mean = 218 mg/dL, SD = ± 35.0 (p < 0.001); PE - mean = 244 mg/dL, SD = 48.2]. There was no significant difference in oxLDL/LDL-C ratio within the three groups (CN: mean = 0.76, SD = 0.24; IUGR: mean = 0.74, SD = 0.12; PE: mean = 0.77, SD = 0.22). CONCLUSION Our results show a lower maternal LDL-C and TC concentration in IUGR pregnancies. These data contribute to the hypothesis of a decreased cholesterol supply to the fetus in IUGR. However, we could not confirm the hypothesis of an altered oxidative state in neither IUGR nor PE.
Collapse
Affiliation(s)
- Ulrich Pecks
- Department of Obstetrics and Gynecology, University Hospital of the RWTH, Aachen, Germany.
| | | | | | | | | | | | | |
Collapse
|
242
|
Untch M, Gerber B, Möbus V, Schneeweiss A, Thomssen C, von Minckwitz G, Beckmann MW, Blohmer JU, Costa SD, Diedrich K, Diel I, Eiermann W, Friese K, Harbeck N, Hilfrich J, Jackisch C, Janni W, Jänicke F, Jonat W, Kaufmann M, Kiechle M, Köhler U, Kreienberg R, Maass N, Marschner N, Nitz U, Scharl A, Wallwiener D. Zurich Consensus: Statement of German Experts on St. Gallen Conference 2011 on Primary Breast Cancer (Zurich 2011). Breast Care (Basel) 2011. [DOI: 10.1159/000327999] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
243
|
von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, de Jongh F, Baumann K, Bischoff J, Harbeck N, Lück HJ, Maass N, Zielinski C, Andersson M, Stein R, Nekljudova V, Loibl S. Abstract P6-14-05: Final Overall Survival Analysis of the TBP Phase III Study (GBG 26/BIG 3-05): Capecitabine vs. Capecitabine + Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing during Trastuzumab Treatment. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p6-14-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In women with HER2-positive breast cancer progressing during trastuzumab treatment, continuation of trastuzumab plus capecitabine (XH) showed a significantly improved overall response rate and time to progression compared with capecitabine (X) alone (von Minckwitz et al, J Clin Oncol 27:1999-2006, 2009). Here we report the final analysis of overall survival (OS).
Methods: Patients (pts) with HER2-positive, locally advanced or metastatic breast cancer who progressed during treatment with trastuzumab with or without adjuvant and/or 1st-line metastatic chemotherapy were prospectively randomized to X (2500 mg/m2 on days 1-14, q3w) or XH (6 mg/kg, q3w). OS was a pre-specified secondary endpoint of the study. Results: Median follow up at June 2010 was 20.7 months. 59 of 74 and 60 of 77 pts died in the X alone and XH arm, respectively. Median OS was 20.6 and 24.9 months with X alone and XH, respectively. This difference was not statistically significant (HR=0.94 [0.65-1.35]; p=0.73). Cox proportional hazard model showed performance status, hormone receptor status and metastatic site as independent prognosticators for survival. No difference between treatment arms was observed for pts with a clinical response or clinical benefit, respectively. Pts who continued/restarted anti-HER2 treatment (trastuzumab or lapatinib) after 2nd progression (N=88) had an OS of 18.8 compared with 13.3 months for those who did not receive 3rd line treatment with anti-HER2 agents (N=52) (HR 0.63; p=0.02). Pts who continued treatment after progression as initially randomized (anti-HER2 treatment after XH (N=31) or no anti-HER2 treatment after X alone (N=53)) had an OS of 26.7 months and 20.4 months (HR 0.71; p=0.2). Conclusions: Final OS analysis of the GBG-26 study could not demonstrate a survival benefit for treatment beyond progression with trastuzumab. However in a post-hoc analysis, pts receiving anti-HER2 treatment as 3rd line therapy showed a better OS than those not receiving this targeted treatment.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P6-14-05.
Collapse
Affiliation(s)
- G von Minckwitz
- German Breast Group, Neu-Isenburg D; UFK Frankfurt D; UFK Mainz D; HSK Wiesbaden D; UFK Kiel D; Inst. of Oncology Ljubljana SLO; Reinier de Graaf Gasthuis Delft & BOOG NL; Akazia Ziekenhuis Rotterdam & BOOG NL; UFK Marburg Klinikum Deggendorf D; UFK Magdeburg D; UFK Köln D; Gyn Praxis Hannover D; UFK Aachen D; Medical University Vienna & CECOG A; Rigshospitalet University Hospital Copenhagen DK; University College London Hospitals UK
| | - K Schwedler
- German Breast Group, Neu-Isenburg D; UFK Frankfurt D; UFK Mainz D; HSK Wiesbaden D; UFK Kiel D; Inst. of Oncology Ljubljana SLO; Reinier de Graaf Gasthuis Delft & BOOG NL; Akazia Ziekenhuis Rotterdam & BOOG NL; UFK Marburg Klinikum Deggendorf D; UFK Magdeburg D; UFK Köln D; Gyn Praxis Hannover D; UFK Aachen D; Medical University Vienna & CECOG A; Rigshospitalet University Hospital Copenhagen DK; University College London Hospitals UK
| | - M Schmidt
- German Breast Group, Neu-Isenburg D; UFK Frankfurt D; UFK Mainz D; HSK Wiesbaden D; UFK Kiel D; Inst. of Oncology Ljubljana SLO; Reinier de Graaf Gasthuis Delft & BOOG NL; Akazia Ziekenhuis Rotterdam & BOOG NL; UFK Marburg Klinikum Deggendorf D; UFK Magdeburg D; UFK Köln D; Gyn Praxis Hannover D; UFK Aachen D; Medical University Vienna & CECOG A; Rigshospitalet University Hospital Copenhagen DK; University College London Hospitals UK
| | - J Barinoff
- German Breast Group, Neu-Isenburg D; UFK Frankfurt D; UFK Mainz D; HSK Wiesbaden D; UFK Kiel D; Inst. of Oncology Ljubljana SLO; Reinier de Graaf Gasthuis Delft & BOOG NL; Akazia Ziekenhuis Rotterdam & BOOG NL; UFK Marburg Klinikum Deggendorf D; UFK Magdeburg D; UFK Köln D; Gyn Praxis Hannover D; UFK Aachen D; Medical University Vienna & CECOG A; Rigshospitalet University Hospital Copenhagen DK; University College London Hospitals UK
| | - C Mundhenke
- German Breast Group, Neu-Isenburg D; UFK Frankfurt D; UFK Mainz D; HSK Wiesbaden D; UFK Kiel D; Inst. of Oncology Ljubljana SLO; Reinier de Graaf Gasthuis Delft & BOOG NL; Akazia Ziekenhuis Rotterdam & BOOG NL; UFK Marburg Klinikum Deggendorf D; UFK Magdeburg D; UFK Köln D; Gyn Praxis Hannover D; UFK Aachen D; Medical University Vienna & CECOG A; Rigshospitalet University Hospital Copenhagen DK; University College London Hospitals UK
| | - T Cufer
- German Breast Group, Neu-Isenburg D; UFK Frankfurt D; UFK Mainz D; HSK Wiesbaden D; UFK Kiel D; Inst. of Oncology Ljubljana SLO; Reinier de Graaf Gasthuis Delft & BOOG NL; Akazia Ziekenhuis Rotterdam & BOOG NL; UFK Marburg Klinikum Deggendorf D; UFK Magdeburg D; UFK Köln D; Gyn Praxis Hannover D; UFK Aachen D; Medical University Vienna & CECOG A; Rigshospitalet University Hospital Copenhagen DK; University College London Hospitals UK
| | - E Maartense
- German Breast Group, Neu-Isenburg D; UFK Frankfurt D; UFK Mainz D; HSK Wiesbaden D; UFK Kiel D; Inst. of Oncology Ljubljana SLO; Reinier de Graaf Gasthuis Delft & BOOG NL; Akazia Ziekenhuis Rotterdam & BOOG NL; UFK Marburg Klinikum Deggendorf D; UFK Magdeburg D; UFK Köln D; Gyn Praxis Hannover D; UFK Aachen D; Medical University Vienna & CECOG A; Rigshospitalet University Hospital Copenhagen DK; University College London Hospitals UK
| | - F de Jongh
- German Breast Group, Neu-Isenburg D; UFK Frankfurt D; UFK Mainz D; HSK Wiesbaden D; UFK Kiel D; Inst. of Oncology Ljubljana SLO; Reinier de Graaf Gasthuis Delft & BOOG NL; Akazia Ziekenhuis Rotterdam & BOOG NL; UFK Marburg Klinikum Deggendorf D; UFK Magdeburg D; UFK Köln D; Gyn Praxis Hannover D; UFK Aachen D; Medical University Vienna & CECOG A; Rigshospitalet University Hospital Copenhagen DK; University College London Hospitals UK
| | - K Baumann
- German Breast Group, Neu-Isenburg D; UFK Frankfurt D; UFK Mainz D; HSK Wiesbaden D; UFK Kiel D; Inst. of Oncology Ljubljana SLO; Reinier de Graaf Gasthuis Delft & BOOG NL; Akazia Ziekenhuis Rotterdam & BOOG NL; UFK Marburg Klinikum Deggendorf D; UFK Magdeburg D; UFK Köln D; Gyn Praxis Hannover D; UFK Aachen D; Medical University Vienna & CECOG A; Rigshospitalet University Hospital Copenhagen DK; University College London Hospitals UK
| | - J Bischoff
- German Breast Group, Neu-Isenburg D; UFK Frankfurt D; UFK Mainz D; HSK Wiesbaden D; UFK Kiel D; Inst. of Oncology Ljubljana SLO; Reinier de Graaf Gasthuis Delft & BOOG NL; Akazia Ziekenhuis Rotterdam & BOOG NL; UFK Marburg Klinikum Deggendorf D; UFK Magdeburg D; UFK Köln D; Gyn Praxis Hannover D; UFK Aachen D; Medical University Vienna & CECOG A; Rigshospitalet University Hospital Copenhagen DK; University College London Hospitals UK
| | - N Harbeck
- German Breast Group, Neu-Isenburg D; UFK Frankfurt D; UFK Mainz D; HSK Wiesbaden D; UFK Kiel D; Inst. of Oncology Ljubljana SLO; Reinier de Graaf Gasthuis Delft & BOOG NL; Akazia Ziekenhuis Rotterdam & BOOG NL; UFK Marburg Klinikum Deggendorf D; UFK Magdeburg D; UFK Köln D; Gyn Praxis Hannover D; UFK Aachen D; Medical University Vienna & CECOG A; Rigshospitalet University Hospital Copenhagen DK; University College London Hospitals UK
| | - H-J Lück
- German Breast Group, Neu-Isenburg D; UFK Frankfurt D; UFK Mainz D; HSK Wiesbaden D; UFK Kiel D; Inst. of Oncology Ljubljana SLO; Reinier de Graaf Gasthuis Delft & BOOG NL; Akazia Ziekenhuis Rotterdam & BOOG NL; UFK Marburg Klinikum Deggendorf D; UFK Magdeburg D; UFK Köln D; Gyn Praxis Hannover D; UFK Aachen D; Medical University Vienna & CECOG A; Rigshospitalet University Hospital Copenhagen DK; University College London Hospitals UK
| | - N Maass
- German Breast Group, Neu-Isenburg D; UFK Frankfurt D; UFK Mainz D; HSK Wiesbaden D; UFK Kiel D; Inst. of Oncology Ljubljana SLO; Reinier de Graaf Gasthuis Delft & BOOG NL; Akazia Ziekenhuis Rotterdam & BOOG NL; UFK Marburg Klinikum Deggendorf D; UFK Magdeburg D; UFK Köln D; Gyn Praxis Hannover D; UFK Aachen D; Medical University Vienna & CECOG A; Rigshospitalet University Hospital Copenhagen DK; University College London Hospitals UK
| | - C Zielinski
- German Breast Group, Neu-Isenburg D; UFK Frankfurt D; UFK Mainz D; HSK Wiesbaden D; UFK Kiel D; Inst. of Oncology Ljubljana SLO; Reinier de Graaf Gasthuis Delft & BOOG NL; Akazia Ziekenhuis Rotterdam & BOOG NL; UFK Marburg Klinikum Deggendorf D; UFK Magdeburg D; UFK Köln D; Gyn Praxis Hannover D; UFK Aachen D; Medical University Vienna & CECOG A; Rigshospitalet University Hospital Copenhagen DK; University College London Hospitals UK
| | - M Andersson
- German Breast Group, Neu-Isenburg D; UFK Frankfurt D; UFK Mainz D; HSK Wiesbaden D; UFK Kiel D; Inst. of Oncology Ljubljana SLO; Reinier de Graaf Gasthuis Delft & BOOG NL; Akazia Ziekenhuis Rotterdam & BOOG NL; UFK Marburg Klinikum Deggendorf D; UFK Magdeburg D; UFK Köln D; Gyn Praxis Hannover D; UFK Aachen D; Medical University Vienna & CECOG A; Rigshospitalet University Hospital Copenhagen DK; University College London Hospitals UK
| | - R Stein
- German Breast Group, Neu-Isenburg D; UFK Frankfurt D; UFK Mainz D; HSK Wiesbaden D; UFK Kiel D; Inst. of Oncology Ljubljana SLO; Reinier de Graaf Gasthuis Delft & BOOG NL; Akazia Ziekenhuis Rotterdam & BOOG NL; UFK Marburg Klinikum Deggendorf D; UFK Magdeburg D; UFK Köln D; Gyn Praxis Hannover D; UFK Aachen D; Medical University Vienna & CECOG A; Rigshospitalet University Hospital Copenhagen DK; University College London Hospitals UK
| | - V Nekljudova
- German Breast Group, Neu-Isenburg D; UFK Frankfurt D; UFK Mainz D; HSK Wiesbaden D; UFK Kiel D; Inst. of Oncology Ljubljana SLO; Reinier de Graaf Gasthuis Delft & BOOG NL; Akazia Ziekenhuis Rotterdam & BOOG NL; UFK Marburg Klinikum Deggendorf D; UFK Magdeburg D; UFK Köln D; Gyn Praxis Hannover D; UFK Aachen D; Medical University Vienna & CECOG A; Rigshospitalet University Hospital Copenhagen DK; University College London Hospitals UK
| | - S. Loibl
- German Breast Group, Neu-Isenburg D; UFK Frankfurt D; UFK Mainz D; HSK Wiesbaden D; UFK Kiel D; Inst. of Oncology Ljubljana SLO; Reinier de Graaf Gasthuis Delft & BOOG NL; Akazia Ziekenhuis Rotterdam & BOOG NL; UFK Marburg Klinikum Deggendorf D; UFK Magdeburg D; UFK Köln D; Gyn Praxis Hannover D; UFK Aachen D; Medical University Vienna & CECOG A; Rigshospitalet University Hospital Copenhagen DK; University College London Hospitals UK
| |
Collapse
|
244
|
Kaufmann M, Maass N, Costa S, Schneeweiß A, Loibl S, Sütterlin M, Schrader I, Gerber B, Bauer W, Wiest W, Tomé O, Distelrath A, Hagen V, Kleine-Tebbe A, Ruckhaeberle E, Mehta K, von Minckwitz G. First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: Results of the MONICA trial. Eur J Cancer 2010; 46:3184-91. [DOI: 10.1016/j.ejca.2010.07.009] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2010] [Revised: 07/05/2010] [Accepted: 07/14/2010] [Indexed: 10/19/2022]
|
245
|
Fasching P, Fehm T, Janni W, Kümmel S, Lüftner D, Lux M, Maass N. Aktuelle Therapie der Patientin mit einem Mammakarzinom. Geburtshilfe Frauenheilkd 2010. [DOI: 10.1055/s-0030-1250437] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
246
|
Pecks U, Brieger M, Schiessl B, Bruno B, Trepels-Kottek S, Maass N, Rath W. T11.3 Cholesterol concentration is significantly decreased in umbilical cord blood in intrauterine growth restricted (IUGR) but not in constitutional small for gestational age (cSGA) neonates. Pregnancy Hypertens 2010. [DOI: 10.1016/s2210-7789(10)60096-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
247
|
Pecks U, Caspers R, Schiessl B, Bauerschlag D, Piroth D, Maass N, Rath W. T11.2 Evaluation of the oxidative state of maternal serum low density lipoproteins in intrauterine growth restriction and preeclampsia. Pregnancy Hypertens 2010. [DOI: 10.1016/s2210-7789(10)60095-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
248
|
Bräutigam K, Biernath-Wüpping J, Bauerschlag DO, von Kaisenberg CS, Jonat W, Maass N, Arnold N, Meinhold-Heerlein I. Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines. J Cancer Res Clin Oncol 2010; 137:875-86. [PMID: 20878528 DOI: 10.1007/s00432-010-0952-2] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2010] [Accepted: 09/16/2010] [Indexed: 01/24/2023]
Abstract
PURPOSE Ovarian cancer accounts for the highest mortality among all gynecological cancers, mainly due to the fast developing chemoresistance. The death ligand TRAIL induces apoptosis and is able to sensitize tumor cells to cytostatic drugs without affecting physiological tissue. Combined treatment of TRAIL and the antidiabetic acting PPARγ ligands was shown to induce apoptosis synergistically in different ovarian cancer cell lines. METHODS To investigate feasible TRAIL-dependent inhibition of proliferation and induction of apoptosis in chemoresistant ovarian cancer cell lines, the drug- and TRAIL-sensitive HEY cell line was utilized to develop subclones with selective resistance against cisplatin, etoposide, docetaxel, paclitaxel, gemcitabine and pemetrexed, as well as against TRAIL as control cell line. Expression of the key factors of the TRAIL signaling pathway, TRAIL receptors 1-4, caspase-8, FLIP and XIAP, was analyzed before and after TRAIL treatment by immunoblotting. RESULTS Cell proliferation experiments showed TRAIL-dependent inhibition that was further increased by combination treatment with the PPARγ ligands. Simultaneous exposure of TRAIL and the PPARγ ligands also resulted in enhanced induction of apoptosis even in partial TRAIL-resistant HEY cell lines. In the parental HEY cell line, additional treatment with the PPARγ ligands led to an increased protein expression of DR5 and a further decline of XIAP expression. CONCLUSION Therefore, the combinational treatment with TRAIL and PPARγ ligands might be a promising experimental therapy because the PPARγ ligands, especially d15-PGJ(2), sensitize drug-resistant ovarian cancer cells to TRAIL-induced apoptosis.
Collapse
Affiliation(s)
- Karen Bräutigam
- Department of Gynecology and Obstetrics, University Hospital Aachen, Pauwelsstr. 30, 52074, Aachen, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
249
|
Bauerschlag DO, Schem C, Tiwari S, Egberts JH, Weigel MT, Kalthoff H, Jonat W, Maass N, Meinhold-Heerlein I. Sunitinib (SU11248) inhibits growth of human ovarian cancer in xenografted mice. Anticancer Res 2010; 30:3355-3360. [PMID: 20944108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
BACKGROUND Treatment of ovarian cancer is still challenging especially in recurrent platinum refractory cases. Sunitinib is a multi tyrosine kinase inhibitor targeting receptors for vascular endothelial growth factor and platelet-derived growth factor which play a role in tumor angiogenesis. It has been approved for the treatment of recurrent gastro intestinal stroma tumors and metastatic renal cancer. MATERIALS AND METHODS In this study, sunitinib was tested for its effectiveness as a single agent in an ovarian cancer xenograft mouse model. Skov3 cells stably expressing firefly luciferase were injected into SCID beige mice. Mice received either 40 mg/kg bodyweight sunitinib or vehicle control. Tumor growth was monitored longitudinally by luciferase signal. RESULTS Sunitinib significantly reduced tumor growth (p=0.0052) and peritoneal metastases, and was associated with a significantly reduced microvessel density count (p<0.001). CONCLUSION These results suggest that clinical trials are warranted for the evaluation of sunitinib for treatment of patients with recurrent or advanced ovarian cancer.
Collapse
Affiliation(s)
- Dirk O Bauerschlag
- Department of Gynecology and Obstetrics, University Hospital Aachen, Pauwelsstraße 30, 52074 Aachen, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
250
|
Weigel MT, Dahmke L, Schem C, Bauerschlag DO, Weber K, Niehoff P, Bauer M, Strauss A, Jonat W, Maass N, Mundhenke C. In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells. BMC Cancer 2010; 10:412. [PMID: 20691121 PMCID: PMC2925350 DOI: 10.1186/1471-2407-10-412] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2010] [Accepted: 08/09/2010] [Indexed: 01/08/2023] Open
Abstract
Background Breast cancer treatment is based on a combination of adjuvant chemotherapy followed by radiotherapy effecting intracellular signal transduction. With the tyrosine kinase inhibitors new targeted drugs are available. Imatinib mesylate is a selective inhibitor of bcr-abl, PRGFR alpha, beta and c-kit. The purpose of this study was to determine whether Imatinib has an influence on the effectiveness of radiotherapy in breast cancer cell lines and if a combination of imatinib with standard chemotherapy could lead to increased cytoreduction. Methods Colony-forming tests of MCF 7 and MDA MB 231 were used to study differences in cell proliferation under incubation with imatinib and radiation. Changes in expression and phosphorylation of target receptors were detected using western blot. Cell proliferation, migration and apoptosis assays were performed combining imatinib with doxorubicin. Results The combination of imatinib and radiotherapy showed a significantly stronger inhibition of cell proliferation compared to single radiotherapy. Differences in PDGFR expression could not be detected, but receptor phosphorylation was significantly inhibited when treated with imatinib. Combination of imatinib with standard chemotherapy lead to an additive effect on cell growth inhibition compared to single treatment. Conclusions Imatinib treatment combined with radiotherapy leads in breast cancer cell lines to a significant benefit which might be influenced through inhibition of PDGFR phosphorylation. Combining imatinib with chemotherapy enhances cytoreductive effects. Further in vivo studies are needed to evaluate the benefit of Imatinib in combination with radiotherapy and chemotherapy on the treatment of breast cancer.
Collapse
Affiliation(s)
- Marion T Weigel
- Department of Obstetrics and Gynecology, Breast Center, University of Kiel, Arnold-Heller Strasse 3, 24105 Kiel, Germany
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|